The Anglo-Swedish company AstraZeneca announces that its COVID-19 vaccine, developed with Oxford University, is completing the final stages of clinical trials with an efficacy of 70% (based on an average of two different administration methods, one with a 90% efficacy in 2,741 people and the other with a 62% efficacy in 8,895 people). Unlike the previous two doses, these doses do not require cold storage and do not use the innovative mRNA technique.
